State of Tennessee Department of Treasury Sells 520 Shares of Repligen Co. (NASDAQ:RGEN)

State of Tennessee Department of Treasury cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 2.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,426 shares of the biotechnology company’s stock after selling 520 shares during the period. State of Tennessee Department of Treasury’s holdings in Repligen were worth $2,652,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. bought a new stake in shares of Repligen in the 4th quarter valued at $29,000. UMB Bank n.a. increased its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares during the period. Global Retirement Partners LLC raised its stake in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Repligen in the fourth quarter valued at $55,000. 97.64% of the stock is owned by institutional investors.

Repligen Trading Down 0.3 %

NASDAQ:RGEN opened at $144.75 on Monday. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The company has a market cap of $8.13 billion, a PE ratio of -283.82, a PEG ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day moving average of $139.80 and a 200-day moving average of $145.94.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RGEN shares. JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group dropped their price target on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Hold” and an average target price of $176.82.

Insiders Place Their Bets

In other news, Director Margaret Pax purchased 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.